

HR 4106

Responsibility in Drug Advertising Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 30, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jul 31, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4106>

Sponsor

Name: Rep. DeLauro, Rosa L. [D-CT-3]

Party: Democratic • **State:** CT • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Jul 30, 2019
Rep. Khanna, Ro [D-CA-17]	D · CA		Jul 30, 2019
Rep. Pappas, Chris [D-NH-1]	D · NH		Aug 2, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 31, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 3180	Identical bill	Jan 9, 2020: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 HR 2452	Related bill	May 31, 2019: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Summary (as of Jul 30, 2019)

Responsibility in Drug Advertising Act of 2019

This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

Actions Timeline

- **Jul 31, 2019:** Referred to the Subcommittee on Health.
- **Jul 30, 2019:** Introduced in House
- **Jul 30, 2019:** Referred to the House Committee on Energy and Commerce.